Results 91 to 100 of about 4,843 (156)

A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia

open access: yesCommunications Medicine
Background Dyslipidemia is a known risk factor for cardiovascular disease. While statins are the primary treatment, some individuals require additional lipid-lowering therapies, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ...
Michael Asger Andersen   +4 more
doaj   +1 more source

Triglyceride levels, alirocumab treatment, and cardiovascular outcomes after an acute coronary syndrome [PDF]

open access: yes
BackgroundIt is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations.ObjectivesThis study sought to examine relations between triglyceride ...
Budaj, A.J.   +21 more
core   +1 more source

Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV: Insights From the CAVIAR Trial. [PDF]

open access: yesJACC Heart Fail
Terada K   +9 more
europepmc   +1 more source

Evaluation and AI-powered prediction of the efficacy of alirocumab use among patients with cardiovascular disease. [PDF]

open access: yesFront Pharmacol
Barakat HE   +7 more
europepmc   +1 more source

Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets. [PDF]

open access: yesFront Med (Lausanne)
Ponte-Negretti CI   +13 more
europepmc   +1 more source

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

open access: yes, 2019
: BACKGROUND The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute
Chumburidze, Vakhtang   +499 more
core  

Home - About - Disclaimer - Privacy